<DOC>
	<DOCNO>NCT00624286</DOCNO>
	<brief_summary>This study design provide 12 week efficacy safety data 150 μg once-daily ( od ) dose indacaterol chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Efficacy Safety Indacaterol Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>• Male female patient age 40 year moderate severe chronic obstructive pulmonary disease ( COPD ) plus 20 packyear smoke history Signed informed consent Postbronchodilator force expiratory volume 1 second ) FEV1 ) ≥ 30 % &lt; 80 % predict FEV1/FVC ( force vital capacity ) &lt; 70 % Exclusion Criteria include : History asthma Prior exposure indacaterol Active cancer history cancer Patients concomitant pulmonary disease Patients diabetes Type I uncontrolled diabetes Type II Patients history long QT syndrome whose QTc interval ( Bazett 's ) measure screen randomization prolong Patients unable successfully use drypowder inhaler device perform spirometry measurements Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
</DOC>